Messig, Michael
Pfizer (United States)
3 papers on CoChat
Most cited papers
- Verified
Cardiovascular Event Reduction Versus New-Onset Diabetes During Atorvastatin Therapy
Waters, D. D., Ho, J. E., Boekholdt, S. M., DeMicco, D. A., Kastelein, J. J. P., Messig, M., Breazna, A., & Pedersen, T. R. (2013) · Journal of the American College of Cardiology
Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 178
- Verified
A comparison of non-HDL and LDL cholesterol goal attainment in a large, multinational patient population: The Lipid Treatment Assessment Project 2
Santos, R. D., Waters, D. D., Tarasenko, L., Messig, M., Jukema, J. W., Chiang, C.-W., Ferrieres, J., & Foody, J. M. (2012) · Atherosclerosis
Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 39
- Verified
Abrupt discontinuation compared with a 1-week taper regimen in depressed outpatients treated for 24 weeks with desvenlafaxine 50 mg/d
Khan, A., Musgnung, J., Ramey, T., Messig, M., Buckley, G., & Ninan, P. T. (2014) · Journal of Clinical Psychopharmacology
Treatment of Major DepressionMental Health Treatment and Access
Cited by 30
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free